Progenity Inc. (NASDAQ: PROG) stock gains by 19.67% in the current market trading session. Progenity is a biotechnology firm that develops products for women’s health, gastrointestinal health, and oral biotherapeutics.
>> 7 Top Picks for the Post-Pandemic Economy <<
PROG stock’ Significant Development
The United States Patent and Trademark Office (USPTO) has granted Progenity U.S. Patent No. 11,112,403 for tests for free and dissociated placental growth factor in the diagnosis of preeclampsia. Techniques, formulations, and equipment for identifying and assessing free and dissociated placental growth factor (PlGF) levels in biological samples are covered by the patent. PlGF is a well-known biomarker for the diagnosis of preeclampsia, and new research has demonstrated the necessity of differentiating between the free and bound versions when examining the complicated physiological pathways involved in the disease.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
The Preecludia test is planned to address a $3 billion annual addressable market in the United States. This test has the ability to be used worldwide as an in vitro diagnostic (IVD) and point-of-care solution. Progenity is considering commercialization prospects for the LDT launch in the United States, as well as IVD embodiments to tap the global opportunity for the Preecludia test, in line with the company’s recent strategic shift. The business earlier declared that the clinical validation study had been completed successfully and that the primary study endpoint had been met, and that the study results would be published in a peer-reviewed medical journal.
Furthermore,
Preeclampsia is the second leading cause of maternal death, with over 700,000 pregnant women experiencing indications of preeclampsia each year. Preeclampsia can lead to compromised organ function, seizures, stroke, and death in the mother, as well as pre-term delivery of the baby if left undetected and poorly managed. Preeclampsia can have a negative impact on one’s health as well as cost a lot of money. Because the signs are common happening in up to 30% of pregnant women in the United States and can easily be attributed to other reasons, preeclampsia is frequently missed or misidentified.